GlycoMimetics, Inc. announced the promotion of Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer. Dr. Feldman joined the company in 2019 and was previously Vice President, Global Clinical Development. Before joining GlycoMimetics, Dr. Feldman served as Chief Medical Officer at Amphivena Therapeutics, Inc., focusing on breakthrough blood cancer treatments and T-cell engagement technologies, and prior to that, he oversaw the myeloid leukemia antibody-drug conjugate (ADC) program at Seattle Genetics, Inc. He has led or participated in the conduct of numerous clinical trials, several leading to U.S. Food and Drug Administration (FDA) approval. Dr. Feldman’s extensive academic career includes a recent position as Professor of Medicine and Director of the Hematological Malignancies Service at Weill-Cornell/New York Presbyterian Hospital, as well as faculty positions at New York Medical College and the University of Texas, MD Anderson Cancer Center. Dr. Feldman has authored over 150 scientific articles and is a former Editor-in Chief of the journal Leukemia Research. He earned his medical degree at New York Medical College and holds a B.A. from Tulane University. Separately, Dr. Helen Thackray, M.D. F.A.A.P., has decided to leave the company to pursue another opportunity. She joined the company 15 years ago, and most recently served as Senior Vice President, Clinical Development and Chief Medical Officer.
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).